New Pfizer Oral GLP-1RA Compound in Ph1
A CT.gov record has been observed for a new Pfizer Ph1 study evaluating multiple escalating oral doses of a novel compound PF-07081532 in T2DM patients and non-T2DM patients with obesity. Below, FENIX provides thoughts on this new trial in the context of oral GLP-1RA pipeline candidates from Pfizer and others.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.